Merit Medical Systems (NASDAQ:MMSI) Issues Earnings Results

Merit Medical Systems (NASDAQ:MMSI) issued its quarterly earnings data on Thursday. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.23, FiscalAI reports. The business had revenue of $418.84 million for the quarter, compared to analysts’ expectations of $405.25 million. Merit Medical Systems had a return on equity of 13.54% and a net margin of 9.03%.The company’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.01 EPS. Merit Medical Systems updated its FY 2026 guidance to 4.250-4.350 EPS.

Here are the key takeaways from Merit Medical Systems’ conference call:

• Merit reported 9% organic constant-currency revenue growth in Q2, its strongest quarterly organic growth in three years, with broad-based strength across foundational and therapeutic products, including vascular intervention, access, cardiac therapies, endoscopy, and OEM.
• Q2 profitability exceeded expectations: non-GAAP operating margin rose to 22.6%, non-GAAP EPS increased 18% to $1.19, and free cash flow reached nearly $52 million. Excluding a $0.09-per-share tariff refund benefit, EPS was still $1.10 and above guidance.
• The company raised its 2026 outlook, now expecting 6.9%-7.6% constant-currency revenue growth and non-GAAP EPS of $4.25-$4.35, versus prior EPS guidance of $4.01-$4.15; organic growth guidance increased to 6.9%-7.5%.
• Acquisitions are performing ahead of expectations: BioLife’s annualized 2026 revenue outlook increased to approximately $23 million, while C2 CryoBalloon remains expected to generate $8 million-$9 million. Merit also launched SCOUT MD and is introducing View Point Medical’s OneMark system to expand its oncology localization offering.
• Management expects third-quarter revenue and EPS to moderate sequentially because of normal summer seasonality, while ongoing tariffs are expected to reduce 2026 results by approximately $16 million, or $0.21 per share; tariff policy uncertainty also contributed to a wider Q3 margin and EPS outlook range.

Merit Medical Systems Trading Up 3.1%

MMSI stock traded up $2.51 during mid-day trading on Thursday, reaching $83.35. 2,024,596 shares of the stock traded hands, compared to its average volume of 691,109. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.46 and a current ratio of 5.08. Merit Medical Systems has a one year low of $59.74 and a one year high of $94.75. The stock has a market capitalization of $4.97 billion, a PE ratio of 36.08, a PEG ratio of 2.51 and a beta of 0.52. The business has a 50-day moving average price of $69.45 and a two-hundred day moving average price of $71.69.

Insider Activity

In other news, insider Brian G. Lloyd bought 2,000 shares of the stock in a transaction dated Thursday, May 7th. The stock was purchased at an average price of $62.62 per share, for a total transaction of $125,240.00. Following the acquisition, the insider owned 2,000 shares of the company’s stock, valued at $125,240. The trade was a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Lynne N. Ward sold 5,000 shares of Merit Medical Systems stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $62.61, for a total transaction of $313,050.00. Following the transaction, the director directly owned 7,809 shares of the company’s stock, valued at approximately $488,921.49. This represents a 39.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of MMSI. Cibc World Markets Corp bought a new stake in shares of Merit Medical Systems during the 4th quarter worth approximately $341,000. Headlands Technologies LLC bought a new position in Merit Medical Systems in the 4th quarter worth about $326,000. FORA Capital LLC purchased a new position in shares of Merit Medical Systems during the second quarter worth approximately $325,000. Lido Advisors LLC increased its position in shares of Merit Medical Systems by 3.8% during the fourth quarter. Lido Advisors LLC now owns 3,836 shares of the medical instruments supplier’s stock worth $324,000 after acquiring an additional 140 shares during the period. Finally, Graham Capital Management L.P. raised its stake in shares of Merit Medical Systems by 23.6% during the fourth quarter. Graham Capital Management L.P. now owns 3,324 shares of the medical instruments supplier’s stock valued at $293,000 after acquiring an additional 635 shares in the last quarter. Hedge funds and other institutional investors own 99.66% of the company’s stock.

Wall Street Analysts Forecast Growth

MMSI has been the topic of several research reports. Needham & Company LLC reduced their price target on shares of Merit Medical Systems from $101.00 to $90.00 and set a “buy” rating on the stock in a research report on Friday, May 1st. Wells Fargo & Company lowered their price objective on shares of Merit Medical Systems from $78.00 to $74.00 and set an “equal weight” rating for the company in a research report on Friday, May 1st. Weiss Ratings downgraded shares of Merit Medical Systems from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 8th. JPMorgan Chase & Co. reduced their target price on shares of Merit Medical Systems from $95.00 to $77.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Finally, Barrington Research decreased their target price on shares of Merit Medical Systems from $109.00 to $107.00 and set an “outperform” rating on the stock in a research report on Monday, April 20th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $92.80.

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.